Hans Tesch

Feb 28, 2024 | futuremedicine.com | Luciano Costa |Thomas W. LeBlanc |Thomas Leblanc |Hans Tesch |Pieter Sonneveld

Multiple myeloma (MM) is a progressive type of malignancy characterized by the rapid accumulation of monoclonal plasma cells mostly in the bone marrow [1]. Patients with MM experience a range of physical symptoms, including pain and fatigue, with many also reporting depression, anxiety and impairment of psychosocial well-being [2,3]. Unfortunately, the long-term prognosis is often poor for these patients, with median survival estimates ranging only from 5 to 7 years [1].